Skip to main content
SpringerLink
Log in

Telavancin

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs).

  • ▴ In randomized, double-blind trials, intravenous telavancin 10 mg/kg once daily (administered as a 1-hour infusion) was effective in the treatment of adult patients with cSSSIs, including those with infections caused by MRSA, as shown by clinical cure rates in clinically evaluable, all-treated and microbiologically evaluable populations at the test-of-cure (TOC) visit.

  • ▴ Telavancin 10 mg/kg once daily was noninferior to intravenous vancomycin 1 g every 12 hours, with clinical cure rates of 88% versus 87% at the TOC visit in pooled data from the clinically evaluable population (n=1489) of two phase III trials.

  • ▴ Pooled clinical cure rates in telavancin recipients at the TOC visit were also not significantly different from those in vancomycin recipients in the all-treated or microbiologically evaluable populations, including microbiologically evaluable subgroups with baseline infections caused by MRSA, meticillin-susceptible S. aureus or other Gram-positive pathogens.

  • ▴ Telavancin was generally well tolerated in patients with cSSSIs, with most adverse events being of mild or moderate severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published errata appear in Clin Infect Dis 2005 Dec 15; 41(12): 1830, and 2006 Apr 15; 42 (8): 1219]. Clin Infect Dis 2005 Nov 15; 41(10): 1373–406

    Article  PubMed  Google Scholar 

  2. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008 Jun 1; 46 Suppl. 5: S368–77

    Article  PubMed  CAS  Google Scholar 

  3. Patel M. Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management. Drugs 2009; 69(6): 693–716

    Article  PubMed  CAS  Google Scholar 

  4. Attwood RJ, LaPlante KL. Telavancin: a novel lipoglyco-peptide antimicrobial agent. Am J Health Syst Pharm 2007 Nov 15; 64(22): 2335–48

    Article  PubMed  CAS  Google Scholar 

  5. Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004 May; 57(5): 326–36

    Article  CAS  Google Scholar 

  6. Lunde CS, Hartouni SR, Janc JW, et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009 Aug; 53(8): 3375–83

    Article  PubMed  CAS  Google Scholar 

  7. Debabov DV, Mammen M, Humphrey PP, et al. Relative inhibitory effects of telavancin on peptidoglycan polymerization and cross-linking in Staphylococcus aureus [abstract no. C1-680]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA), 76

  8. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005 Mar; 49(3): 1127–34

    Article  PubMed  CAS  Google Scholar 

  9. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.] J Antimicrob Chemother 2006 Aug; 58(2): 338–43

    Article  PubMed  CAS  Google Scholar 

  10. Barcia-Macay M, Lemaire S, Mingeot-Leclercq M-P, et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vanco-mycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006 Dec; 58(6): 1177–84

    Article  PubMed  CAS  Google Scholar 

  11. Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005 Jan; 49(1): 195–201

    Article  PubMed  CAS  Google Scholar 

  12. Vibativ (telavancin) for injection, for intravenous use: US prescribing information. Deerfield (IL): Astellas Pharma US, Inc., 2009 Sep

  13. Sahm DF, Benton BM, Cohen MA, et al. Interaction of telavancin and other antimicrobial agents tests against key Gram-positive species [abstract no. E-718]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA), 180

  14. Sahm DF, Benton BM, Cohen MA, et al. Telavancin demonstrates a low potential for in vitro selection of resistance among key target Gram-positive species [abstract no. C1-681]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA), 76

  15. Krause K, Debabov D, Pace J, et al. Low frequency of spontaneous resistance to TD-6424 and delayed resistance selection in vitro among staphylococci and enterococci [abstract no. C1-1810]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14–17; Chicago (IL), 96

  16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2009 Jan

    Google Scholar 

  17. Theravance, Inc. Astellas and Theravance announce approval of Vibativ(TM) (telavancin) in Canada for the treatment of complicated skin and skin structure infections [online]. Available from URL: http://investor.theravance.com/releasedetail.cfm?ReleaseID=412892 [Accessed 2009 Oct7]

  18. Draghi DC, Benton BM, Krause KM, et al. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008 Jul; 52(7): 2383–8

    Article  PubMed  CAS  Google Scholar 

  19. Draghi DC, Benton BM, Krause KM, et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004–05 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008 Jul; 62(1): 116–21

    Article  PubMed  CAS  Google Scholar 

  20. Finegold SM, Bolanos M, Sumannen PH, et al. In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates. Antimicrob Agents Chemother 2009 Sep; 53(9): 3996–4001

    Article  PubMed  CAS  Google Scholar 

  21. Tsuji BT, Leonard SN, Rhomberg PR, et al. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn Microbiol Infect Dis 2008 Apr; 60(4): 441–4

    Article  PubMed  CAS  Google Scholar 

  22. Odenholt I, Löwdin E, Cars O. Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum, and in an in vitro kinetic model. Antimicrob Agents Chemother 2007 Sep; 51(9): 3311–6

    Article  PubMed  CAS  Google Scholar 

  23. Kosowska-Shick K, Clark C, Pankuch GA, et al. Activity of telavancin against staphylococci and enterococci by MIC and resistance selection studies. Antimicrob Agents Chemother 2009 Mar; 53(10): 4217–24

    Article  PubMed  CAS  Google Scholar 

  24. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008 Jun 1; 46(11): 1683–93

    Article  PubMed  CAS  Google Scholar 

  25. Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob Agents Chemother 2008 Jul; 52(7): 2647–52

    Article  PubMed  CAS  Google Scholar 

  26. Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003 Nov; 47(11): 3602–4

    Article  PubMed  CAS  Google Scholar 

  27. Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2007 Aug; 60(2): 406–9

    Article  PubMed  CAS  Google Scholar 

  28. Pankuch GA, Appelbaum PC. Postantibiotic effects of telavancin against 16 gram-positive organisms. Antimicrob Agents Chemother 2009; 53(3): 1275–7

    Article  PubMed  CAS  Google Scholar 

  29. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob Agents Chemother 2004 Aug; 48(8): 3043–50

    Article  PubMed  CAS  Google Scholar 

  30. Lubenko IY, Strukova EV, Smirnova MV, et al. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother 2008 Nov; 62(5): 1065–9

    Article  PubMed  CAS  Google Scholar 

  31. Sun HK, Duchin K, Nightingale CH, et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006 Feb; 50(2): 788–90

    Article  PubMed  CAS  Google Scholar 

  32. Duchin K, Shaw J, Spencer E, et al. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction [abstract no P1028]. Clin Microbiol Infect 2004 May; 10 Suppl. 3: 276. Plus poster presented at the 14th European Congress of Clinical Microbiology and Infectious Diseases; 2004 May 1–4; Prague

    Google Scholar 

  33. Wong SL, Sörgel F, Kinzig M, et al. Lack of pharmaco-kinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol 2009 Jul; 49(7): 816–23

    Article  PubMed  CAS  Google Scholar 

  34. Stryjewski ME, O’Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 2005 Jun 1; 40(11): 1601–7

    Article  PubMed  CAS  Google Scholar 

  35. Stryjewski ME, Chu VH, O’Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006 Mar; 50(3): 862–7

    Article  PubMed  CAS  Google Scholar 

  36. Campbell SJ, Deshmukh HS, Nelson CL, et al. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol 2008 Feb; 46(2): 678–84

    Article  PubMed  CAS  Google Scholar 

  37. Wilson SE, O’Riordan W, Hopkins A, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg 2009 Jun; 197(6): 791–6

    Article  PubMed  CAS  Google Scholar 

  38. Fowler Jr VG, Rude T, Nelson C, et al. Activity of telavancin against Staphylococcus aureus isolates carrying the Panton-Valentine leukocidin gene in the ATLAS studies [abstract no. P847]. 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 Mar 31–Apr 3; Munich

  39. Laohavaleeson S, Barriere SL, Nicolau DP, et al. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy 2008 Dec; 28(12): 1471–82

    Article  PubMed  Google Scholar 

  40. Barriere S, Genter F, Spencer E, et al. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004 Jul; 44(7): 689–95

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by: G.R. Corey, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA; J.M. Embil, Section of Infectious Diseases, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; F. Van Bambeke, Unité de pharmacologie cellulaire et moléculaire, Université catholique de Louvain, Brussels, Belgium.

The preparation of this review was not supported by any external funding.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Katherine A. Lyseng-Williamson & Stephanie K. A. Blick

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie K. A. Blick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A., Blick, S.K.A. Telavancin. Drugs 69, 2607–2620 (2009). https://doi.org/10.2165/10481380-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/10481380-000000000-00000

Keywords

Search

Navigation